AMBIOPHARM acquired by CORDENPHARMA

CordenPharma, backed by private equity firm Astorg since 2022, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China. The transaction is part of CordenPharma’s broader strategy to strengthen its position as a global leader in peptide therapeutics manufacturing, a high-growth segment driven by next-generation pharmaceutical innovation, including GLP-1 and other advanced peptide-based therapies. The acquisition adds complementary capabilities across solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid synthesis technologies, as well as downstream purification and lyophilization capacities. The combination significantly expands CordenPharma’s industrial footprint, adding a second US-based peptide manufacturing site and establishing a strategic presence in Shanghai, complementing its existing global network of 11 manufacturing and R&D facilities across Europe and North America. It also enhances supply chain flexibility for customers, offering multiple regional and global production models.